AstraZeneca targets 2024 growth but mixed views hit shares
AstraZeneca expects to boost 2024 revenue and profit on the back of its blockbuster cancer drugs, but lower than expected...
Read moreAstraZeneca expects to boost 2024 revenue and profit on the back of its blockbuster cancer drugs, but lower than expected...
Read more
